Nantkwest (NK) Hits New 1-Year Low at $1.56

Nantkwest Inc (NASDAQ:NK) reached a new 52-week low on Thursday . The company traded as low as $1.56 and last traded at $1.57, with a volume of 1932 shares traded. The stock had previously closed at $1.67.

A number of equities research analysts recently weighed in on the stock. Citigroup lowered their target price on shares of Nantkwest to $3.00 in a report on Sunday, December 2nd. Jefferies Financial Group restated a “hold” rating and issued a $3.50 target price on shares of Nantkwest in a report on Thursday, November 15th. ValuEngine upgraded shares of Nantkwest from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research upgraded shares of Nantkwest from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Wednesday, October 10th. Finally, BidaskClub upgraded shares of Nantkwest from a “sell” rating to a “hold” rating in a research note on Friday, September 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.58.

The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.31 and a current ratio of 3.31. The company has a market cap of $132.31 million, a P/E ratio of -1.30 and a beta of 3.09.

In other Nantkwest news, Director Steve Gorlin sold 151,159 shares of the stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $1.74, for a total value of $263,016.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 469,251 shares of company stock valued at $919,880. Company insiders own 72.30% of the company’s stock.

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Nantkwest by 132.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 111,641 shares of the biotechnology company’s stock worth $413,000 after purchasing an additional 63,689 shares during the last quarter. Millennium Management LLC increased its stake in shares of Nantkwest by 402.4% during the 1st quarter. Millennium Management LLC now owns 156,744 shares of the biotechnology company’s stock worth $610,000 after purchasing an additional 125,544 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Nantkwest by 40.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock worth $521,000 after purchasing an additional 49,040 shares during the last quarter. Bridgeway Capital Management Inc. increased its stake in shares of Nantkwest by 75.0% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 175,000 shares of the biotechnology company’s stock worth $648,000 after purchasing an additional 75,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Nantkwest by 144.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 216,272 shares of the biotechnology company’s stock worth $662,000 after buying an additional 127,694 shares during the period. Institutional investors own 13.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Nantkwest (NK) Hits New 1-Year Low at $1.56” was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.wkrb13.com/2018/12/07/nantkwest-nk-hits-new-1-year-low-at-1-56.html.

About Nantkwest (NASDAQ:NK)

NantKwest, Inc, a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

See Also: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply